First line immunotherapy for liver cancer! Roche tecentriq + Avastin has a strong curative effect, with a total remission rate of 36% and a 45% reduction in the risk of disease progression / death

September 28, 2019 / BIOON / - the annual meeting of the European Society of Oncology (ESMO) in 2019 was held in Barcelona, Spain, from September 27 to October 1 At the meeting, Roche, a Swiss pharmaceutical giant, released data from the stage IB cancer immunotherapy combination study (nct02715531) This is an open label, multicenter study that is evaluating tumor immunotherapy tecentriq (atezolizumab, anti-PD-L1 antibody) in combination with Avastin and / or other drugs for solid tumor patients Group A (non randomized) and group F (randomized) of the study were enrolled in patients with previously untreated unresectable liver cell carcinoma (HCC) All patients in group a received tecentriq + Avastin combined therapy, while those in group F received tecentriq and Avastin combined therapy or tecentriq single drug treatment in a ratio of 1:1 Data from group A showed that the primary efficacy end point of objective response rate (ORR) was achieved: after a median follow-up of 12.4 months, the combination of tecentriq and Avastin showed clinically significant and lasting remission, and RECIST was used V1.1) the orr was 36% (95% CI: 26-46), the CR was 12%, and the median duration of remission (DOR) was not reached At the secondary end point, the median progression free survival (PFS) was 7.3 months (95% CI: 5.4-9.9) as confirmed by the central review using RECIST v1.1 In terms of safety, the safety of tecentriq combined with Avastin seems to be consistent with the known safety of each drug No new safety signals were found Data from group F showed that the primary efficacy end point of PFS was achieved: recest v1.1 was used for central review, and the combination of recentriq and Avastin reduced the risk of disease progression or death by 45% compared with the single drug treatment of recentriq The median follow-up of 6.6 months showed that the combination of tecentriq and Avastin was superior to the single drug treatment (HR = 0.55, 80% CI: 0.40-0.74, P = 0.0108) The median PFS was 5.6 months (95% CI: 3.6-7.4) in the combination therapy group and 3.4 months (95% CI: 1.9-5.2) in the single drug therapy group Two other secondary endpoints of group F are under evaluation, and the data are not mature at present The safety of the two queues in group F seemed to be consistent with that of each known drug No new safety signals were found Sandra horning, chief medical officer and head of global product development, MD, said: "we are encouraged by these latest results, which show that in patients with unresectable HCC, progression free survival and confirmed objective response rate are very promising, especially for this disease, which does not meet the medical needs These data enhance our confidence in the combination therapy of tecentriq and Avastin for this common liver cancer, and we look forward to the results from the phase III study imbrave150 " In July 2018, according to the data of phase IB study, FDA of the United States awarded tecentriq and Avastin initial (first-line) breakthrough drug qualification (BTD) for advanced or metastatic liver cancer (HCC) Earlier this year, patients enrolled in the imbrave150 (nct03434379) study, an open label, multicenter, randomized phase III study in patients with unresectable HCC who had not previously received systematic treatment, are investigating the efficacy and safety of the combination of tecentriq and Avastin over the multi kinase inhibitor sorafenib The study is expected to publish its results later this year Roche has developed a wide range of clinical trial development projects for tecentriq, including ongoing or planned studies, including multiple phase III studies, involving various types of lung cancer, urogenital system cancer, skin cancer, breast cancer, gastrointestinal cancer, gynecological cancer and head and neck cancer This includes studies to evaluate the single drug of tecentriq and its combination with other drugs Tecentriq belongs to PD - (L) 1 tumor immunotherapy It aims to bind to a protein named PD-L1 expressed on tumor cells and tumor infiltrating immune cells, and block its interaction with PD-1 and B7.1 receptors By inhibiting PD-1, tecentriq can activate T cells, which has the potential to be used as a basic combination therapy for cancer immunotherapy, targeted drugs and various cancer chemotherapy Avastin is a kind of angiogenesis inhibitor, targeting to combine with vascular endothelial growth factor (VEGF) VEGF plays an important role in angiogenesis and maintenance in tumor life cycle Avastin can directly bind to VEGF to infect the blood supply of tumor and prevent it from interacting with receptors on vascular cells Tumor blood supply is considered to be the key to tumor growth and metastasis in vivo The combination of tecentriq and Avastin has a strong scientific basis, and the combination of tecentriq and Avastin has the potential to enhance the immune system against tumor Avastin not only has the established anti angiogenic effect, but also can further enhance tecentriq's ability to recover the body's anti-cancer immunity by inhibiting VEGF related immunosuppression, promoting tumor infiltration of T cells and activating the response of T cells to tumor antigens In December 2018, the US FDA approved tecentriq + Avastin + chemotherapy (carboplatin and paclitaxel) for the first-line treatment of adult patients with metastatic non squamous non-small cell lung cancer (NSQ NSCLC) without EGFR or ALK genomic tumor distortion This approval is based on data from patients in group B of the impower 150 study: in patients with intention to treat wild-type (itt-wt), tecentriq + Avastin + chemotherapy significantly prolonged the survival of patients compared with Avastin + chemotherapy (median OS: 19.2 months vs 14.7 months, HR = 0.78, P = 0.016) Source of the original text: Roche's tecentriq in combination with Avastin shows intensifying results in phase IB study of people with unexpected HPA